Additional Heparin Preadministration Improves Cardiac Glucose Metabolism Suppression over Low-Carbohydrate Diet Alone in ^{18}F-FDG PET Imaging

Asbjørn M. Scholtens[1], Hein J. Verberne[2], Ricardo P.J. Budde[3], and Marnix G.E.H. Lam[4]

[1]Department of Radiology and Nuclear Medicine, Meander Medical Center, Amersfoort, The Netherlands; [2]Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; [3]Department of Radiology, Erasmus Medical Center, Rotterdam, The Netherlands; and [4]Department of Imaging, University Medical Center Utrecht, Utrecht, The Netherlands

Adequate suppression of cardiac glucose metabolism increases the interpretability and diagnostic reliability of ^{18}F-FDG PET studies performed to detect cardiac inflammation and infection. There are no standardized guidelines, though prolonged fasting (>6 h), carbohydrate-restricted diets, fatty meals, and heparin loading all have been proposed. The aim of this study was to compare the 3 preparatory protocols used in our institution. **Methods:** ^{18}F-FDG PET scans were selected and grouped according to 3 preparatory protocols (50 consecutive scans per group): 6-h fast (group 1), low-carbohydrate diet plus 12-h fast (group 2), and low-carbohydrate diet plus 12-h fast plus intravenous heparin preadministration (50 IU/kg) (group 3). Consecutive scans were retrospectively included from time frames during which the particular protocol was used. Group 1 included oncologic indications, and groups 2 and 3 infection or inflammation detection. Cardiac segments for which inflammation or infection foci had been confirmed on other imaging modalities were excluded from the analysis. ^{18}F-FDG uptake in normal myocardium was scored according to a scale ranging from 0 (uptake less than that in left ventricle blood pool) to 4 (diffuse uptake greater than that in liver). Adequate suppression was defined as uptake less than that in liver and without any focus (scores 0–2). **Results:** Adequate suppression differed significantly between groups: 28% in group 1, 54% in group 2, and 88% in group 3 ($P < 0.0001$ for all comparisons). **Conclusion:** Single-dose heparin administration before ^{18}F-FDG PET in addition to a low-carbohydrate diet significantly outperforms a low-carbohydrate diet alone in adequately suppressing cardiac glucose metabolism.

Key Words: FDG-PET; cardiac glucose metabolism; low carbohydrate diet; heparin; sarcoidosis; endocarditis

For detecting cardiac infection and cardiac involvement in sarcoidosis, ^{18}F-FDG PET with CT attenuation correction (PET/CT)

has been proposed as an important imaging modality (*1–3*), most notably diagnosing pacemaker lead and prosthetic heart valve infection (*4–7*). These disease entities are associated with high morbidity and mortality rates, and adequate diagnosis is of the utmost importance in guiding therapeutic decisions.

When ^{18}F-FDG PET is used to diagnose cardiac and pericardiac inflammation or infection, it is important to differentiate between pathologic uptake of ^{18}F-FDG in lesions and physiologic uptake of ^{18}F-FDG in normal myocardium. Uptake in normal myocardium is dependent mainly on insulin, blood glucose levels, and blood free fatty acid (FFA) levels in accordance with the Randle cycle (*8*). Elevated insulin and blood glucose levels and decreased FFA levels lead to a relative rise in myocardial glucose consumption, whereas during fasting, an increase in FFA levels and a decrease in insulin and glucose levels shifts myocardial energy consumption away from glucose and toward FFA. Type 4 cellular glucose transporter (GLUT4) mediates the latter inhibitory effect, whereas it is mainly GLUT1 and GLUT3 that mediate the increased glucose consumption of inflammatory cell responses. By manipulating the GLUT4 response, it is possible to suppress physiologic myocardial glucose consumption independently of inflammatory processes.

Several methods to suppress cardiac glucose metabolism have been reported: prolonged intervals of fasting (leading to a decrease in blood glucose and insulin levels and, eventually, an increase in blood FFA levels), low-carbohydrate diets (minimizing blood glucose and insulin levels), fat-rich meals (elevating blood FFA levels), heparin administration (inducing lipolysis in vivo and up to a 5-fold increase in blood FFA levels (*9*)), and combinations of these methods (*10–19*). To date, no standard protocol has been adopted, although combination protocols have been advocated by some studies and recent reviews (*2,3*).

The aim of this study was to compare the efficacy of 3 methods of cardiac suppression: the standard oncologic preparation (≥6-h fast, group 1), a low-carbohydrate diet alone (group 2), and a low-carbohydrate diet with heparin preadministration (group 3).

MATERIALS AND METHODS

Patient Selection

In our hospital, a low-carbohydrate diet including prolonged fasting (≥12 h) was applied as the protocol of choice for cardiac suppression from 2008 to early 2013. Because of a relatively high number of scans with unsatisfactory cardiac suppression, heparin preadministration (50 IU/kg of body weight intravenously 15 min before administration of ^{18}F-FDG) was added to the protocol in 2013.

TABLE 1
Group Characteristics

Characteristic	Group 1 (malignancy)		Group 2 (sarcoidosis/FUO)		Group 3 (sarcoidosis/FUO)		One-way ANOVA	Post hoc Bonferroni		
	Mean	SD	Mean	SD	Mean	SD		1 vs. 2	1 vs. 3	2 vs. 3
Age (y)	55.3 (range, 15–81)	—	55.2 (range, 13–81)	—	56.5 (range, 24–80)	—	0.908	1.00	1.00	1.00
Serum glucose (mmol/L)	6.4	2.0	6.3	1.6	6.2	1.7	0.837	1.00	1.00	1.00
Weight (kg)	71.4	16.3	79.7	14.8	82.2	14.3	0.001	0.022	0.001	1.00
Body mass index	24.06	4.46	26.61	4.64	26.08	4.46	0.014	0.016	0.081	1.00
Body surface area	1.84	0.24	1.95	0.22	2.01	0.20	0.001	0.040	0.001	0.539

FUO = fever of unknown origin.

n = 50 per group.

At the time of analysis, 50 scans had been performed with heparin preadministration and were included as group 3. For comparison with group 3, each of groups 1 and 2 included 50 consecutive scans from among those most recently performed. In group 1 all scans were performed for oncologic indications; in groups 2 and 3 the indications were either sarcoidosis or fever of unknown origin with possible cardiac involvement. Weight, body mass index, and body surface area were measured before the ^{18}F-FDG PET/CT scan (Table 1). Because all data were retrospectively gathered from standard clinical procedures, review was not deemed necessary by the local ethics committee.

Imaging

Groups 2 and 3 followed the same carbohydrate-restricted, fat- and protein-allowed diet for at least 12 h before a fast of at least 12 h. Fifteen minutes before ^{18}F-FDG administration (2 MBq/kg), group 3 additionally received a 50 IU/kg intravenous dose of heparin. All scans were performed at the University Medical Center Utrecht on the same ^{18}F-FDG PET/CT system (Biograph mCT; Siemens) approximately 60 min after administration of ^{18}F-FDG. Before the PET acquisition, unenhanced CT images were obtained for attenuation correction. PET was performed using 3-dimensional acquisition, a field of view of 216 mm, and a scanning time of 3 min/bed position; low-dose CT for attenuation correction was performed using a 1.0 pitch, a 10-mm slice thickness, 120 kV, and 40 mAs. The PET/CT data were reconstructed using iterative ordered-subsets expectation maximization (gaussian filter, 4 iterations, 21 subsets).

Scoring

Figure 1 shows a flowchart of the scoring process. To measure the effects on normal myocardium alone, cardiac areas with proven or highly probable sarcoidosis or infectious lesions based on elevated ^{18}F-FDG uptake and correlation with lesions on MRI, contrast-enhanced CT, or transesophageal echocardiography were excluded from the analysis. The number excluded was only 12 of a possible 2,550 segments (0.5%) (0 scans in group 1, 4 scans in group 2 [6 excluded segments total], and 5 scans in group 3 [6 excluded segments total]).

Scoring was performed by a nuclear medicine specialist with 8 y of experience in cardiac imaging and a nuclear medicine physician in training, both of whom were masked to the patient preparation method but had full access to the entire scan. In cases of disagreement, the two interpreters reached a consensus to produce the final score used in the analysis.

First, uptake in the heart as a whole was scored according to a visual scale (Table 2). Scores of 0, 1, and 2 signified cardiac suppression

adequate for clinical evaluation. A score of 3, signifying partially inadequate cardiac suppression (focal uptake difficult to distinguish from cardiac inflammation), was additionally scored according to the 17-segment model to analyze uptake patterns. In this additional scoring model, because the distinction between diffuse and focal distribution does not apply to a segmental model, scores of 3 and 4 were conflated and the segmental score was adjusted to one of the following: 0 (uptake < ventricular blood pool uptake), 1 (uptake = ventricular blood pool uptake), 2 (uptake > ventricular blood pool uptake but < liver uptake), and 3 (uptake > liver uptake).

Statistics

Continuous variables were compared between groups using 1-way ANOVA with post hoc Bonferroni analysis. Categoric visual scores


FIGURE 1. Visual scoring flowchart.

TABLE 2
Scoring Scale

Score	Uptake criterion
0	Myocardium less than left ventricular blood pool
1	Myocardium equal to left ventricular blood pool
2	Myocardium greater than left ventricular blood pool but less than liver
3	Myocardium focally greater than liver
4	Myocardium diffusely greater than liver

were compared between groups using the Pearson χ^2 test. *P* values below 0.05 were considered statistically significant, except in the Bonferroni analysis, for which *P* values below 0.0167 (0.05/3) were considered significant.

RESULTS

Age and mean blood glucose level did not differ significantly between groups (Table 1). Weight was moderately but significantly lower in group 1 than in groups 2 and 3, with body mass index and body surface area being significantly different or trending toward a significant difference accordingly. There were no significant differences between groups 2 and 3. The scores for the 3 groups are shown in Table 3 and Figure 2.

There was little disagreement between the 2 interpreters, with only 6 of 150 scans scored differently in terms of adequate versus inadequate suppression. Four of these 6 scans showed diffuse myocardial activity nearly equal to liver activity, leading the first interpreter to score them as 2 and the second interpreter as 4. The other 2 scans had very small focal lesions that were missed by one of the interpreters, changing the scores from 1 to 4.

Twenty-five representative axial images for each group are compared in Figure 3, revealing the significant decrease in the number of scans showing intense cardiac uptake. Although the low-carbohydrate diet with prolonged fasting statistically improved cardiac suppression compared with the standard preparation ($P < 0.0001$), the improvement in cardiac suppression in the heparin group was significantly larger not only compared with the standard preparation ($P < 0.0001$) but also compared with diet alone ($P < 0.0001$). Adequate cardiac suppression (score ≤ 2) rose from 54% after diet alone to 88% after diet with heparin preadministration.

TABLE 3
Visual Assessment Scores per Group

Score	Group 1	Group 2	Group 3
0	7 (14%)	18 (36%)	34 (68%)
1	1 (2%)	3 (6%)	5 (10%)
2	6 (12%)	6 (12%)	5 (10%)
3	11 (22%)	10 (20%)	4 (8%)
4	25 (50%)	13 (26%)	2 (4%)

In scans showing a nondiffuse distribution of myocardial uptake (25/150), the most common uptake patterns in descending order of frequency were lateral wall including apex, mid-to-basal lateral wall alone, and basal ring. Mean and median scores per segment are shown in Figure 4, confirming these patterns.

DISCUSSION

To the best of our knowledge, this is the first study to compare a low-carbohydrate diet plus a fast of at least 12 h with and without heparin preadministration to a standard 6-h fast without dietary modifications. In our analysis, the addition of a 50 IU/kg intravenous dose of heparin 15 min before administration of ^{18}F-FDG significantly increased cardiac suppression compared with both the standard protocol and the low-carbohydrate-diet-alone protocols.

In general, scans with diffusely intense myocardial uptake should be considered nondiagnostic for cardiac inflammatory disease because physiologic uptake effectively masks any possible foci of pathologic uptake, as shown in Figure 5. Conversely, scans with focal or focal-on-diffuse physiologic uptake may be falsely interpreted as indicating cardiac disease. By minimizing the number of scans with these uptake patterns, the heparin preadministration protocol probably improves the accuracy of ^{18}F-FDG PET/CT for detection of pericardiac or cardiac infection and inflammation. Additionally, because the absence of cardiac uptake may be interpreted as an absence of active myocardial inflammatory disease, a more consistently adequate method of cardiac suppression could diminish the need for additional studies such as myocardial perfusion scintigraphy or cardiac MRI to rule out cardiac involvement. An important exception to this approach is the detection of cardiac-valve infectious vegetations, which reports indicate are not detected by ^{18}F-FDG PET (*4,5*). Care should be taken not to exclude the presence of infectious vegetations on the basis of negative ^{18}F-FDG PET findings alone.

Although heparin preadministration improved cardiac suppression, a minority of scans still showed suboptimal suppression. Because adherence to the protocol was self-reported, we cannot exclude the possibility that some patients did not adhere to their diet as well as they reported. However, it may be hypothesized that any lack of adherence to the diet will be equally distributed over the groups. It therefore seems unlikely that differences in adherence alone explain the differences found in this study.

FIGURE 2. Visual score distribution per group.

FIGURE 3. Representative distribution of findings in each group.

FIGURE 4. Mean (A) and median (B) uptake scores per segment in scans with nondiffuse uptake.

Other factors known to influence cardiac glucose uptake are the presence of myocardial ischemia and heart failure. Ischemia leads to locally enhanced glucose consumption due to several factors: glucose oxidation yields a greater amount of adenosine triphosphate per mole of oxygen than FFA does; a small amount of adenosine triphosphate is generated through glycolysis independently of oxygen supply; and glucose transport is enhanced in oxygen-deprived tissue (20). In heart failure, a generic shift occurs from FFA toward glucose as the preferred fuel (21). However, none of the patients in this study had clinically suspected myocardial ischemia or were known to have heart failure at the time of the scan. Although the presence of these factors should be accounted for when cardiac ^{18}F-FDG PET is interpreted, it is unlikely that they played a significant role in our analysis.

Although body weight was significantly lower in group 1 than in groups 2 and 3 (likely because of the cachectic effects of malignancy), possibly leading to differences in glucose metabolism, lowered body weight would theoretically lead to lower available serum glucose, which in turn would shift cardiac metabolism toward FFA consumption and does not explain the higher prevalence of unsuppressed myocardium in this group.

Our findings on analyzing the patterns of ^{18}F-FDG distribution in physiologically nondiffuse cardiac uptake (score of 3) are in keeping with earlier publications (22–24). Knowledge of these variable patterns of nonpathologic uptake is important in the interpretation of ^{18}F-FDG PET scans for cardiac inflammatory or infectious disease when cardiac suppression may not be adequate.

Limitations

Although the retrospective nature of this study and the relatively low number of patients per group limits statistical power, the differences between groups were still highly significant. Nevertheless, our findings should ideally be validated in a larger, prospective trial.

SUV analysis was not performed, as we believe such an analysis would provide no added benefit to the assessment of normal myocardium and the effects of these preparatory protocols. Reporting a mean or median SUV for each group does not incorporate the high variability in uptake, both with regard to intensity and with regard to location, among subjects (Fig. 2). Also, it may be difficult to delineate the true uptake in adequately suppressed myocardium, leaving such measurements relatively prone to error. We believe the visual uptake score is the most reliable and important variable for this analysis.

We did not perform an in-depth analysis of the medications used by the different patient groups. Although differences in medication could theoretically influence cardiac glucose metabolism, this influence is likely limited when protocols are strictly adhered to and is unlikely to explain the highly statistically significant differences among the 3 groups of this study.

Safety Considerations

Because unfractionated heparin is an anticoagulant, the major safety consideration is the risk of bleeding disorders. In

FIGURE 5. Consecutive maximum-intensity projections of patient with cardiac sarcoidosis (A and B) and patient with prosthetic heart valve endocarditis (C and D). In both patients, inflammatory foci (arrows) are almost completely masked (right) unless physiologic myocardial ^{18}F-FDG uptake is adequately suppressed (left).

a metaanalysis on thromboprophylaxis by Martel et al., the risk of heparin-induced thrombocytopenia from unfractionated heparin was calculated at 2.6%, but the durations of heparin therapy (range, 6–30 d) were far beyond the single bolus administered in our protocol (25). Although carrying a lower risk of heparin-induced thrombocytopenia, low-molecular-weight heparin has been shown to produce a rise in FFA levels inferior to that of unfractionated heparin, probably making it less suitable for cardiac suppression (9).

A study evaluating prophylactic anticoagulation during peripheral intervention (with a heparin dose more closely approximating our protocol) found major and minor bleeding complications of 0.9% and 9.0%, respectively (26), but all complications were related to the arterial access site and therefore not applicable to our protocol, in which no arterial puncture was performed. In our patient group, no bleeding complications were reported.

Although special attention should be given to patients who already receive anticoagulant therapy or have a history of bleeding disorders, the added value for cardiac suppression of a single bolus of unfractionated heparin certainly appears to outweigh the low associated risk of bleeding disorders in most patients. It is possible that this risk can be minimized further, as intravenous administration of heparin has been shown to induce a rise in serum FFA levels at doses below the threshold for anticoagulant effects. In one study, 15 IU/kg more than doubled the FFA concentration while having hardly any effect on the partial thromboplastin time in 5 healthy volunteers (27). In that study, FFA levels plateaued at 15–25 IU/kg, the latter being the highest dose tested. It is unknown whether this plateau is maintained at 50 IU/kg or whether FFA levels rise further. If a dose of 15 IU/kg does indeed elicit a rise in serum FFA levels adequate to suppress myocardial glucose metabolism to the same extent as 50 IU/kg did in our data, heparin preadministration can be incorporated into the protocol without adding any risk of bleeding disorders. Future studies comparing these two doses are needed.

CONCLUSION

A low-carbohydrate diet and prolonged fasting combined with heparin preadministration suppresses cardiac glucose metabolism significantly better than diet and prolonged fasting alone, leading to improved interpretability of ^{18}F-FDG PET scans performed for the detection of cardiac inflammation or infection.

DISCLOSURE

ACKNOWLEDGMENT

REFERENCES

1. Ishida Y, Yoshinaga K, Miyagawa M, et al. Recommendations for ^{18}F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society of Nuclear Cardiology recommendations. *Ann Nucl Med.* 2014;28:393–403.
2. Schatka I, Bengel FM. Advanced imaging of cardiac sarcoidosis. *J Nucl Med.* 2014;55:99–106.
3. Skali H, Schulman AR, Dorbala S. ^{18}F-FDG PET/CT for the assessment of myocardial sarcoidosis. *Curr Cardiol Rep.* 2013;15:352.
4. Saby L, Laas O, Habib G, et al. Positron emission tomography/computed tomography for diagnosis of prosthetic valve endocarditis: increased valvular ^{18}F-fluorodeoxyglucose uptake as a novel major criterion. *J Am Coll Cardiol.* 2013;61:2374–2382.
5. Tanis W, Scholtens A, Habets J, et al. CT angiography and ^{18}F-FDG-PET fusion imaging for prosthetic heart valve endocarditis. *JACC Cardiovasc Imaging.* 2013;6:1008–1013.
6. Chen W, Kim J, Molchanova-Cook OP, Dilsizian V. The potential of FDG PET/CT for early diagnosis of cardiac device and prosthetic valve infection before morphologic damages ensue. *Curr Cardiol Rep.* 2014;16:459.
7. Ploux S, Riviere A, Amraoui S, et al. Positron emission tomography in patients with suspected pacing system infections may play a critical role in difficult cases. *Heart Rhythm.* 2011;8:1478–1481.
8. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. *Lancet.* 1963;1:785–789.
9. Persson E, Nordenstrom J, Nilsson-Ehle P, Hagenfeldt L, Wahren J. Plasma lipolytic activity and substrate oxidation after intravenous administration of heparin and a low molecular weight heparin fragment. *Clin Physiol.* 1990;10:573–583.
10. Morooka M, Moroi M, Uno K, et al. Long fasting is effective in inhibiting physiological myocardial ^{18}F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. *EJNMMI Res.* 2014;4:1-219X-4-1.
11. Soussan M, Brillet PY, Nunes H, et al. Clinical value of a high-fat and low-carbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis. *J Nucl Cardiol.* 2013;20:120–127.
12. Kobayashi A, Shinozaki T, Shinjyo Y, et al. FDG PET in the clinical evaluation of sarcoidosis with bone lesions. *Ann Nucl Med.* 2000;14:311–313.
13. Ito K, Morooka M, Okazaki O, Minaminoto R, Kubota K, Hiroe M. Efficacy of heparin loading during an ^{18}F-FDG PET/CT examination to search for cardiac sarcoidosis activity. *Clin Nucl Med.* 2013;38:128–130.
14. Gormsen LC, Christensen NL, Bendstrup E, Tolbod LP, Nielsen SS. Complete somatostatin-induced insulin suppression combined with heparin loading does not significantly suppress myocardial ^{18}F-FDG uptake in patients with suspected cardiac sarcoidosis. *J Nucl Cardiol.* 2013;20:1108–1115.

15. Coulden R, Chung P, Sonnex E, Ibrahim Q, Maguire C, Abele J. Suppression of myocardial ^{18}F-FDG uptake with a preparatory "Atkins-style" low-carbohydrate diet. *Eur Radiol.* 2012;22:2221–2228.

16. Cheng VY, Slomka PJ, Ahlen M, Thomson LE, Waxman AD, Berman DS. Impact of carbohydrate restriction with and without fatty acid loading on myocardial ^{18}F-FDG uptake during PET: a randomized controlled trial. *J Nucl Cardiol.* 2010;17:286–291.

17. Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting ^{18}F-FDG PET-CT in the detection of cardiac sarcoidosis. *J Nucl Cardiol.* 2009;16:801–810.

18. Williams G, Kolodny GM. Suppression of myocardial ^{18}F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. *AJR.* 2008;190:W151–W156.

19. Okumura W, Iwasaki T, Toyama T, et al. Usefulness of fasting ^{18}F-FDG PET in identification of cardiac sarcoidosis. *J Nucl Med.* 2004;45:1989–1998.

20. Garfein O. *Current Concepts in Cardiovascular Physiology.* Burlington, Vermont: Elsevier Science; 1990:565.

21. Dávila-Román VG, Vedala G, Herrero P, et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. *J Am Coll Cardiol.* 2002;40:271–277.

22. Gropler RJ, Siegel BA, Lee KJ, et al. Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. *J Nucl Med.* 1990; 31:1749–1756.

23. Maurer AH, Burshteyn M, Adler LP, Steiner RM. How to differentiate benign versus malignant cardiac and paracardiac ^{18}F FDG uptake at oncologic PET/CT. *Radiographics.* 2011;31:1287–1305.

24. Maurer AH, Burshteyn M, Adler LP, Gaughan JP, Steiner RM. Variable cardiac [18]FDG patterns seen in oncologic positron emission tomography computed tomography: importance for differentiating normal physiology from cardiac and paracardiac disease. *J Thorac Imaging.* 2012;27:263–268.

25. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. *Blood.* 2005;106:2710–2715.

26. Sheikh IR, Ahmed SH, Mori N, et al. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in percutaneous peripheral intervention: a single-center experience. *JACC Cardiovasc Interv.* 2009;2:871–876.

27. Asmal AC, Leary WP, Thandroyen F, Botha J, Wattrus S. A dose-response study of the anticoagulant and lipolytic activities of heparin in normal subjects. *Br J Clin Pharmacol.* 1979;7:531–533.